Navigation Links
Favrille to Host Conference Call and Live Webcast to Discuss First Quarter 2008 Financial Results on May 8, 2008
Date:5/1/2008

SAN DIEGO, May 1 /PRNewswire-FirstCall/ -- Favrille, Inc. (Nasdaq: FVRL), a biopharmaceutical company developing patient-specific, active immunotherapies for the treatment of cancer, announced today that it will host a conference call and live webcast at 5:00 p.m. Eastern Time on Thursday, May 8, 2008 to discuss the Company's first quarter 2008 financial results. A press release will be issued after the U.S. stock markets close that day.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080404/LAF521LOGO)

A live audio webcast of management's presentation will be available on the Investor Relations section of the Company's web site at http://www.favrille.com. Alternatively, callers may participate in the conference call by dialing (888) 713-4205 or (617) 213-4862, passcode 61931952. To pre-register for this call, please go to https://www.theconferencingservice.com/prereg/key.process?key=PFYXYBR33. Callers who pre-register will be given a unique PIN to gain immediate access to the call and bypass the live operator. You may pre-register at any time, including up to and after the call start time. A telephone replay of the call will also be available for 48 hours. The telephone replay can be accessed by dialing (888) 286-8010 or (617) 801-6888, passcode 61738291.

About Favrille, Inc.

Favrille, Inc. is a biopharmaceutical company focused on the development and commercialization of targeted immunotherapies for the treatment of cancer and other diseases of the immune system. The Company's lead product candidate, Specifid(TM) (formerly FavId(R)), is based upon unique genetic information extracted from a patient's tumor. Specifid is currently under investigation in a Phase 3 registration trial for patients with follicular B-cell non-Hodgkin's lymphoma (NHL) and Phase 2 clinical trials in other B-cell NHL indications. The Company is developing additional applications based on its immunotherapy expertise and proprietary cost-effective manufacturing technology, including a second product candidate, FAV-201, for the treatment of cutaneous T-cell lymphoma.


'/>"/>
SOURCE Favrille, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Favrille Reports Fourth Quarter and Year End 2007 Financial Results
2. Favrille Announces $21.1 Million Registered Direct Offering
3. Favrille to Present at BIOCOM Investor Conference, Acumen BioFin Rodman & Renshaw Healthcare Conference and CIBC World Markets Healthcare Conference
4. Favrille to Host Conference Call and Live Webcast to Discuss Third Quarter 2007 Financial Results on October 25, 2007
5. Favrille to Present at BIO InvestorForum
6. Favrille to Present at AG Edwards Emerging Growth Conference and Wall Street Analyst Forum
7. Favrille CEO to Present at Bear Stearns Healthcare Conference
8. Favrille CEO to Present at NewsMakers in the Biotech Industry Investment Conference
9. Amylin Pharmaceuticals Announces Time Change to Previously Announced Presentation at the Morgan Stanley Global Healthcare Unplugged Conference
10. Gen-Probe to Webcast Presentation at Deutsche Bank 33rd Annual Health Care Conference
11. InterMune to Present at Deutsche Bank Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... 2017 BD (Becton, Dickinson and Company) (NYSE: ... will host a live webcast of its Annual Meeting of Shareholders ... The webcast can be accessed from the BD corporate website ... January 31, 2017. ... About BD BD is a global medical technology company ...
(Date:1/18/2017)... According to a new market research report "In situ Hybridization Market by Technique ... Diagnostic Laboratories, Academic and Research Institutions) - Global Forecast to 2021" published by ... USD 557.1 Million in 2016, growing at a CAGR of 5.8%. ... ... MarketsandMarkets Logo ...
(Date:1/18/2017)... Applied BioMath ( www.appliedbiomath.com ), the ... and development, today announced that Dr. John ... Applied BioMath, will present at the next Boston ... on Thursday January 19, 2017 at the Broad ... Dr. Burke,s talk "Quantitative Modeling and Simulation Approaches: ...
(Date:1/18/2017)... ... January 18, 2017 , ... Executive search ... in its continued commitment to the advancement of the clinical trials segment. Hosted ... related to clinical trial planning and management. , As executive talent specialists ...
Breaking Biology Technology:
(Date:12/15/2016)... 2016 "Increase in mobile transactions is driving ... biometrics market is expected to grow from USD 4.03 ... at a CAGR of 29.3% between 2016 and 2022. ... growing demand for smart devices, government initiatives, and increasing ... component is expected to grow at a high rate ...
(Date:12/8/2016)... 8, 2016 Market Research Future published a half cooked ... Mobile Biometric Security and Service Market is expected to grow over ... Market Highlights: ... Mobile Biometric Security and Service ... increasing need of authentication and security from unwanted cyber threats. The ...
(Date:12/7/2016)... India , December 7, 2016 According to a ... Machine Learning), Software Tool (Facial Expression, Voice Recognition), Service, Application Area, End User, ... is estimated to grow from USD 6.72 Billion in 2016 to USD 36.07 ... Continue Reading ... ...
Breaking Biology News(10 mins):